タイプ2糖尿病:グローバル医薬品市場予測・分析(~2022)...市場調査レポートについてご紹介

【英文タイトル】PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 11
1.1 List of Tables 19
1.2 List of Figures 27
2 Introduction 29
2.1 Catalyst 29
2.2 Related Reports 30
3 Disease Overview 31
3.1 Etiology and Pathophysiology 31
3.1.1 Etiology 31
3.1.2 Pathophysiology 32
3.1.3 Prognosis 33
3.1.4 Quality of Life 34
3.2 Symptoms 34
4 Epidemiology 36
4.1 Risk Factors and Comorbidities 36
4.1.1 Family history of diabetes is a strong predictor of type 2 diabetes 37
4.1.2 The risk of type 2 diabetes increases dramatically around age 50 38
4.1.3 The risk of developing type 2 diabetes increases as BMI increases 39
4.1.4 Gestational diabetes increases the risk of developing type 2 diabetes later in life up to 10 times 40
4.1.5 Up to 75% of adults with type 2 diabetes have hypertension 41
4.1.6 Nearly all type 2 diabetics also have dyslipidemia 42
4.2 Global Trends 43
4.2.1 US 43
4.2.2 5EU 47
4.2.3 Japan 50
4.2.4 Brazil 52
4.2.5 China and India 52
4.3 Forecast Methodology 54
4.3.1 Sources Used 57
4.3.2 Forecast Assumptions and Methods 67
4.3.3 Sources Not Used 76
4.4 Epidemiology Forecast of Type 2 Diabetes (2012-2022) 77
4.4.1 Prevalent Cases of Diagnosed Type 2 Diabetes 77
4.4.2 Age-Specific Prevalent Cases of Diagnosed Type 2 Diabetes 79
4.4.3 Sex-Specific Prevalent Cases of Diagnosed Type 2 Diabetes 81
4.4.4 Age-Standardized Prevalence of Diagnosed Type 2 Diabetes 83
4.4.5 Overweight/Obesity among Diagnosed Prevalent Cases of Type 2 Diabetes 84
4.4.6 Hypertension among Diagnosed Prevalent Cases of Type 2 Diabetes 86
4.4.7 Dyslipidemia among Diagnosed Prevalent Cases of Type 2 Diabetes 88
4.5 Discussion 89
4.5.1 Limitations of the Analysis 92
4.5.2 Strengths of the Analysis 93
5 Disease Management 95
5.1 Treatment Overview 95
5.1.1 Diagnosis and Referrals 95
5.1.2 Treatment Guidelines 96
5.2 US 102
5.2.1 Diagnosis 102
5.2.2 Clinical Practice 102
5.3 France 103
5.3.1 Diagnosis 103
5.3.2 Clinical Practice 103
5.4 Germany 104
5.4.1 Diagnosis 104
5.4.2 Clinical Practice 104
5.5 Italy 106
5.5.1 Diagnosis 106
5.5.2 Clinical Practice 107
5.6 Spain 109
5.6.1 Diagnosis 109
5.6.2 Clinical Practice 109
5.7 UK 110
5.7.1 Diagnosis 110
5.7.2 Clinical Practice 112
5.8 Japan 114
5.8.1 Diagnosis 114
5.8.2 Clinical Practice 114
5.9 China 115
5.9.1 Diagnosis 115
5.9.2 Clinical Practice 116
5.10 India 117
5.10.1 Diagnosis 117
5.10.2 Clinical Practice 117
5.11 Brazil 118
5.11.1 Diagnosis 118
5.11.2 Clinical Practice 118
6 Competitive Assessment 119
6.1 Overview 119
6.2 Strategic Competitor Assessment 120
6.3 Product Profiles – Major Brands 122
6.3.1 Metformin 122
6.3.2 Sulfonylureas (SUs) and Other Insulin Secretagogues 127
6.3.3 α-glucosidase Inhibitors (AGIs) 133
6.3.4 Thiazolidinediones (TZDs) 137
6.3.5 GLP-1 Receptor Agonists 142
6.3.6 DPP-4 Inhibitors 165
6.3.7 SGLT-2 Inhibitors 194
6.3.8 Insulin Formulations 204
7 Opportunity and Unmet Need 231
7.1 Overview 231
7.2 Unmet Needs 232
7.2.1 Drugs Providing Sustained Glycemic Control 232
7.2.2 Drugs with Non-Glycemic Benefits 233
7.2.3 Increased Patient Compliance 234
7.2.4 Drugs with Improved Side-Effect Profiles 235
7.2.5 Earlier Diagnosis 236
7.3 Unmet Needs Gap Analysis 237
7.4 Oral Therapy with Sustainable Efficacy 238
7.5 Oral Therapy Offering Weight Loss 238
7.6 Cardio-metabolic Therapy 239
7.7 Promotion of Type 2 Diabetes Drugs in Emerging Markets 239
8 Pipeline Assessment 240
8.1 Overview 240
8.2 Clinical Trial Mapping 241
8.2.1 Clinical Trials by Country 241
8.3 Clinical Trials by Phase and Trial Status 242
8.4 Promising Drugs in Clinical Development 244
8.4.1 Albiglutide 248
8.4.2 Dulaglutide (LY2189265) 254
8.4.3 Semaglutide 261
8.4.4 Trelagliptin (SYR-472) 266
8.4.5 MK-3102 270
8.4.6 Empagliflozin 275
8.4.7 Tofogliflozin 281
8.4.8 Ipragliflozin 286
8.4.9 LY2409021 291
8.4.10 LY2605541 (insulin peglispro) 296
9 Current and Future Players 302
9.1 Overview 302
9.2 Trends in Corporate Strategy 305
9.3 Company Profiles 306
9.3.1 Eli Lilly 306
9.3.2 Bristol-Myers Squibb 309
9.3.3 Novo Nordisk 313
9.3.4 Sanofi 316
9.3.5 GlaxoSmithKline 318
9.3.6 AstraZeneca 320
9.3.7 Merck & Co 322
9.3.8 Boehringer Ingelheim 324
9.3.9 Takeda 326
9.3.10 Roche 329
9.3.11 Pfizer 330
9.3.12 Johnson & Johnson 332
10 Market Outlook 334
10.1 Global Markets 334
10.1.1 Forecast 334
10.1.2 Drivers and Barriers – Global Issues 339
10.2 US 340
10.2.1 Forecast 340
10.2.2 Key Events 345
10.2.3 Drivers and Barriers 346
10.3 France 348
10.3.1 Forecast 348
10.3.2 Key Events 352
10.3.3 Drivers and Barriers 353
10.4 Germany 355
10.4.1 Forecast 355
10.4.2 Key Events 359
10.4.3 Drivers and Barriers 360
10.5 Italy 361
10.5.1 Forecast 361
10.5.2 Key Events 365
10.5.3 Drivers and Barriers 366
10.6 Spain 367
10.6.1 Forecast 367
10.6.2 Key Events 371
10.6.3 Drivers and Barriers 372
10.7 UK 374
10.7.1 Forecast 374
10.7.2 Key Events 378
10.7.3 Drivers and Barriers 379
10.8 Japan 381
10.8.1 Forecast 381
10.8.2 Key Events 385
10.8.3 Drivers and Barriers 386
10.9 China 388
10.9.1 Forecast 388
10.9.2 Key Events 392
10.9.3 Drivers and Barriers 393
10.10 India 395
10.10.1 Forecast 395
10.10.2 Key Events 399
10.10.3 Drivers and Barriers 399
10.11 Brazil 402
10.11.1 Forecast 402
10.11.2 Key Events 406
10.11.3 Drivers and Barriers 406
11 Appendix 410
11.1 Bibliography 410
11.2 Abbreviations 442
11.3 Methodology 445
11.4 Forecasting Methodology 445
11.4.1 Diagnosed Type 2 Patients 446
11.4.2 Percent Drug-Treated Patients 446
11.4.3 Drugs Included in Each Therapeutic Class 446
11.4.4 Launch and Patent Expiry Dates 447
11.4.5 General Pricing Assumptions 448
11.4.6 Individual Drug Assumptions 449
11.4.7 Generic Erosion 458
11.4.8 Pricing of Pipeline Agents 458
11.5 Physicians and Specialists Included in this Study 460
11.6 About the Authors 462
11.6.1 Analyst II – CVMD 462
11.6.2 Therapy Director – CVMD and Infectious Disease 462
11.6.3 Senior Epidemiologist 463
11.6.4 Global Head of Healthcare 463
11.7 About GlobalData 464
11.8 Disclaimer 464


【レポート販売概要】

■ タイトル:タイプ2糖尿病:グローバル医薬品市場予測・分析(~2022)
■ 英文:PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
■ 発行日:2014年1月31日
■ 調査会社:GlobalData
■ 商品コード:GDHC76PIDR
■ 調査対象地域:グローバル
  • アジア太平洋の移動式クレーン市場2016-2020
    About Mobile Crane Mobile cranes are used to lift and transport different types of load at construction sites. They are mounted on a rubber-tire or crawler carrier and can be powered by electric motors or internal combustion engines. The mobile crane market in APAC is one of the steadily growing construction equipment markets in the world. Technavio’s analysts forecast the mobile crane market in A …
  • HVACエアダクトの世界市場2017-2021
    About HVAC Air Ducts Heating, ventilation, and air conditioning (HVAC) is one of the most energy-intensive systems in commercial and residential buildings. Air ducts are conduits or passages used in HVAC to distribute and ventilate air. Supply air, return air, and exhaust air are the needed airflows in an HVAC system that flow through HVAC air ducts. Ducts commonly also deliver ventilation air alo …
  • 化学産業向けカスタマイズドグリーン倉庫の世界市場2018-2022
    About Customized Green Warehouse Facility for Chemical Industry The global customized green warehouse facility market for the chemical industry uses sustainable and environment-friendly warehousing techniques and functions for optimizing the storage and flow of goods. This is achieved by reducing the waste, checking the carbon emission, and the discharge of harmful effluents from chemical warehous …
  • ネットワークテレメトリーの世界市場予測(~2024年)
    Increasing need for in-depth visibility into network security and Quality of Service (QoS), and growing network infrastructure to drive the market growth of network telemetry solutions The global network telemetry market size is expected to grow from 140 million in 2019 to USD 704 million by 2024, at a Compound Annual Growth Rate (CAGR) of 38.1% during the forecast period. Primary factors expected …
  • 自動車産業向けロボットの世界市場予測(~2021):種類別(多関節、直角座標、SCARA、 円筒座標)、構成要素別、用途別、地域別
    The global automotive industry is characterized by the ever increasing competition and rising costs especially experienced by OEM’s and component suppliers. To effectively combat the changing dynamics particularly growing labor costs, robotics solutions are being preferred by automotive manufacturers. The global automotive robotics market is estimated to be USD 5.07 billion in 2016, and is project …
  • Dermatitis:グローバル臨床試験レビューH2, 2013
    Dermatitis Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Dermatitis Global Clinical Trials Review, H2, 2013" provides data on the Dermatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dermatitis. It includes an overview of the trial numbers and their recruitment status as per the site of tri …
  • マイクロタービンの世界市場予測(~2022年):電力定格、用途、エンドユーザー、地域別分析
    The micro turbines market is estimated to be USD 159.7 Million in 2017. It is projected to grow at a CAGR of 9.46%, from 2017 to 2022, to reach a market size of USD 251.0 Million by 2022. The growing demand for clean energy, accompanied by aging grid infrastructure, has led to the growth of the micro turbines market. The burning of conventional energy sources such as petroleum and coal has been id …
  • インベストメント鋳造のグローバル市場動向(2014-2018)
    About Investment Casting Investment casting is an industrial process in which high technology waxes are used to form patterns that allow the production of components with accuracy, repeatability, versatility, and integrity in a variety of metals and high-performance alloys. TechNavio's analysts forecast the Global Investment Casting market will grow at a CAGR of 5.68 percent over the period 2014-2 …
  • ポリマー充填剤の世界市場2017-2021
    ABSTRACTAbout Polymer Fillers Polymer fillers market is about filler materials that are added to other base materials such as rubbers, paper, plastics, and concrete to enhance their reinforcement properties. They reduce overall product cost while enhancing the reinforcement properties of plastics, adhesives, sealants, rubbers, paints, concrete, and paper. Fillers are particles that are added to ma …
  • シェアードサービスの世界市場2016-2020
    About the Shared Services Market The concept of shared services was designed to manage single or multiple functions of business units by sharing information and resources. SSCs manage the functions of business units of organizations. SSCs can be set up anywhere on the globe depending on the business requirements of clients. However, the location of SSCs is a strategic decision taken by an organiza …
  • 不織布/織物の世界市場:スパンボンド不織布、湿式不織布、乾式不織布
    MarketsandMarkets projects that the market for non-woven fabrics is projected to grow from USD 32.7 Billion in 2015 to USD 47.7 Billion by 2020, at a CAGR of 7.86%. The market for non-woven fabrics is growing due to innovative developments in the industrial sectors, growth in the hygiene and medical industry, and rising demand for eco-friendly and high-performing products. Increasing awareness amo …
  • 工業用酵素の世界市場:セルラーゼ、アミラーゼ、プロテアーゼ、リパーゼ
    The market for technical enzymes is projected to reach ~USD 1.27 Billion by 2021, at a CAGR of about 3.4% from 2016 to 2021. The technical enzymes market is fueled by the growing industrialization, increasing environmental concerns, and focus on cost reduction and resource optimization which has led to a large-scale adoption of technical enzymes for various applications. The technical enzymes mark …
  • Yervoy (Non-Small Cell Lung Cancer):市場予測と分析(~2022)
    Yervoy (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment lands …
  • 微生物学的検査/臨床微生物学の世界市場:実験室用計器、自動微生物検査装置、消耗品(検査キット・試薬)
    In this report, the global clinical microbiology market is segmented on the basis of products and applications. On the basis of products, the clinical microbiology market is segmented into consumables and instruments. Each of these market segments is further divided into multiple product segments and subsegments. The clinical microbiology consumables is further bifurcated into kits and reagents, w …
  • 世界のポリヒドロキシアルカノエート市場
    Rising demand of biodegradable materials, positive attitude of governments towards green procurement policies, and rising oil prices are attracting companies to invest in PHA (Polyhydroxyalkanoate) market. Many large companies such as Meredian (U.S.), Ecomann (China), and Bio-on (Italy) are focusing on increasing production capacities. Large number of companies, particularly small and middle-sized …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。